Apichope Pharmaceutical's Subsidiary Gains FDA Approval for Clinical Trial of Innovative Drug APH04935 Tablets
Stock News
Oct 08
Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) has announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd. ("Apichope Pharma"), recently received a letter from the U.S. Food and Drug Administration (FDA) approving the clinical trial of APH04935 tablets, an innovative drug independently developed by the subsidiary.
APH04935 tablets are a highly active and highly selective small molecule GLP-1R (Glucagon-like Peptide-1 Receptor) agonist independently developed by the company. The drug is intended to become a once-daily oral small molecule GLP-1R agonist, designed for weight control and long-term weight management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.